These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24828336)

  • 1. MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
    Munshi SU; Panda H; Holla P; Rewari BB; Jameel S
    PLoS One; 2014; 9(5):e95920. PubMed ID: 24828336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
    J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
    BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
    Rewari BB; Bachani D; Rajasekaran S; Deshpande A; Chan PL; Srikantiah P
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):610-4. PubMed ID: 20890211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma MicroRNA Signature Panel Predicts the Immune Response After Antiretroviral Therapy in HIV-Infected Patients.
    Lv JN; Li JQ; Cui YB; Ren YY; Fu YJ; Jiang YJ; Shang H; Zhang ZN
    Front Immunol; 2021; 12():753044. PubMed ID: 34887859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
    HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
    PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
    Nii-Trebi NI; Ibe S; Barnor JS; Ishikawa K; Brandful JA; Ofori SB; Yamaoka S; Ampofo WK; Sugiura W
    PLoS One; 2013; 8(8):e71972. PubMed ID: 23977189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD
    Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
    AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
    Gare J; Ryan CE; David M; Timbi D; Kaima P; Kombati Z; Imara U; Kelly-Hanku A; Siba PM; Crowe SM; Hearps AC
    J Antimicrob Chemother; 2014 Aug; 69(8):2183-6. PubMed ID: 24722838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.
    Tanuma J; Matsumoto S; Haneuse S; Cuong DD; Vu TV; Thuy PTT; Dung NT; Dung NTH; Trung NV; Kinh NV; Oka S
    J Int AIDS Soc; 2017 Dec; 20(4):. PubMed ID: 29211347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.
    Witwer KW; Watson AK; Blankson JN; Clements JE
    Retrovirology; 2012 Jan; 9():5. PubMed ID: 22240256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
    Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
    Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma microRNA expression levels in HIV-1-positive patients receiving antiretroviral therapy.
    Marquez-Pedroza J; Cárdenas-Bedoya J; Morán-Moguel MC; Escoto-Delgadillo M; Torres-Mendoza BM; Pérez-Ríos AM; González-Enriquez GV; Vázquez-Valls E
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32319513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
    Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
    Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.